abstract：BACKGROUND:Reduction in plasma low-density lipoprotein cholesterol (LDL-C) is a fundamental treatment for the prevention of acute coronary syndromes (ACS). Although statin therapy confers significant protection against ACS in both primary and secondary prevention, a considerable residual risk remains after intensive th...

journal_title：Clinical therapeutics

authors： Sahebkar A,Watts GF

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Many active pharmaceutical ingredients taste bitter and thus are aversive to children as well as many adults. Encapsulation of the medicine in pill or tablet form, an effective method for adults to avoid the unpleasant taste, is problematic for children. Many children cannot or will not swallow solid dose fo...

journal_title：Clinical therapeutics

authors： Mennella JA,Spector AC,Reed DR,Coldwell SE

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Diabetes mellitus (DM) is a powerful independent risk factor for multivessel, diffuse coronary artery disease (CAD). The optimal coronary revascularization strategy in DM is not clearly defined, but past trials have suggested an advantage for coronary artery bypass grafting (CABG). Recently, the Future Revas...

journal_title：Clinical therapeutics

authors： Burgess SN,Mussap CJ,French JK

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Patients' adherence to antiosteoporotic drug therapy is essential to prevent fracture and complications of osteoporosis over the long term. The guidance given in treating osteoporosis can potentially enhance adherence. OBJECTIVE:This study was conducted to compare adherence to osteoporosis regimens by patie...

journal_title：Clinical therapeutics

authors： Cheng TT,Yu SF,Hsu CY,Chen SH,Su BY,Yang TS

更新日期：2013-07-01 00:00:00

abstract：BACKGROUND:In vitro studies have demonstrated that ticagrelor, an oral antiplatelet agent, is a substrate, activator, and inhibitor of cytochrome P450 (CYP) 3A. Thus, potential CYP3A-mediated drug-drug interactions may occur. OBJECTIVES:The goal of this article was to report study results on the effect of ticagrelor o...

journal_title：Clinical therapeutics

authors： Teng R,Butler K

更新日期：2013-07-01 00:00:00

abstract：BACKGROUND:The effectiveness of a drug is significantly influenced by a patient's adherence to the required regimen. OBJECTIVE:The goal of this retrospective database analysis was to determine the factors affecting adherence over a 12-month follow-up period in adults with type 2 diabetes mellitus (DM) initiating once-...

journal_title：Clinical therapeutics

authors： Malmenäs M,Bouchard JR,Langer J

更新日期：2013-06-01 00:00:00

abstract：BACKGROUND:Numerous studies have shown that plasma exchange (PE) is effective as second-line treatment of severe exacerbations of multiple sclerosis (MS) or other idiopathic inflammatory demyelinating diseases of the central nervous system that are nonresponsive to steroid therapy. OBJECTIVE:The goal of this study was...

journal_title：Clinical therapeutics

authors： Meca-Lallana JE,Hernández-Clares R,León-Hernández A,Genovés Aleixandre A,Cacho Pérez M,Martín-Fernández JJ

更新日期：2013-04-01 00:00:00

abstract：BACKGROUND:Since its implementation in 2006, Medicare Part D has evolved from a program that offered basic access to covered drugs for beneficiaries to one that has the potential to affect patient outcomes. OBJECTIVES:The purpose of this article was to highlight key research findings on Medicare Part D published in 20...

journal_title：Clinical therapeutics

authors： Stubbings J,Lau DT

更新日期：2013-04-01 00:00:00

abstract：BACKGROUND:In the treatment of chronic obstructive pulmonary disease (COPD), tiotropium bromide has a longer duration of action than ipratropium bromide; however, tiotropium bromide is a more expensive alternative treatment. At issue is whether tiotropium reduces the risk for hospital readmissions for COPD compared wit...

journal_title：Clinical therapeutics

authors： Kawasumi Y,Paterson MJ,Morrow RL,Miller TA,Bassett K,Wright JM,Dormuth CR

更新日期：2013-04-01 00:00:00

abstract：BACKGROUND:Empagliflozin is a sodium glucose cotransporter 2 inhibitor in clinical development as a treatment for type 2 diabetes mellitus. OBJECTIVE:The goal of this study was to investigate potential drug-drug interactions between empagliflozin and verapamil, ramipril, and digoxin in healthy volunteers. METHODS:The...

journal_title：Clinical therapeutics

authors： Macha S,Sennewald R,Rose P,Schoene K,Pinnetti S,Woerle HJ,Broedl UC

更新日期：2013-03-01 00:00:00

abstract：:Patients with diabetes are responsible for the vast majority of management requirements of their condition. However, their ability and motivation to engage in required self-management behaviors may be mitigated by multiple intrinsic and extrinsic factors. Intrinsic barriers include attitudes and health beliefs, limite...

journal_title：Clinical therapeutics

authors： Rodriguez KM

更新日期：2013-02-01 00:00:00

abstract：BACKGROUND:The antiepileptic drug ezogabine (EZG; US adopted name for retigabine [the international nonproprietary name]) reduces neuronal excitability by enhancing potassium channel activity. EZG has been approved as adjunctive treatment for adults with partial-onset seizures. OBJECTIVE:The goal of this study was to ...

journal_title：Clinical therapeutics

authors： Crean CS,Tompson DJ

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:According to prescribing information for rheumatoid arthritis (RA) treatments in the United States, infliximab should be administered at weeks 1, 2, 6, and then every 8 weeks starting at a 3-mg/kg dose, with flexible dosing up to 10 mg/kg and/or every 4 weeks based on clinical response. OBJECTIVE:This study...

journal_title：Clinical therapeutics

authors： Bolge SC,Carter CT,Mueller CS,Bailey RA,Ingham MP

更新日期：2012-12-01 00:00:00

abstract：BACKGROUND:Technologies in which a remote trigger is used to release drug from an implanted or injected device could enable on-demand release profiles that enhance therapeutic effectiveness or reduce systemic toxicity. A number of new materials have been developed that exhibit sensitivity to light, ultrasound, or elect...

journal_title：Clinical therapeutics

authors： Timko BP,Kohane DS

更新日期：2012-11-01 00:00:00

abstract：BACKGROUND:Inhibitors of dipeptidyl peptidase (DPP) IV are a class of oral hypoglycemic agents that increase glucagon-like peptide-1 (GLP-1) levels by inhibiting its degradation. OBJECTIVE:This study evaluated the pharmacokinetics, pharmacodynamics, and tolerability of DA-1229, which is a newly developed DPP IV inhibi...

journal_title：Clinical therapeutics

authors： Kim TE,Lim KS,Park MK,Yoon SH,Cho JY,Shin SG,Jang IJ,Yu KS

更新日期：2012-09-01 00:00:00

abstract：BACKGROUND:Varenicline was designed to relieve symptoms of nicotine withdrawal, including cigarette craving, and to block the reinforcing effects of continued nicotine use. The cost-effectiveness of varenicline in some countries has not been studied. OBJECTIVE:The aim of this study was to compare the cost-effectivenes...

journal_title：Clinical therapeutics

authors： Athanasakis K,Igoumenidis M,Karampli E,Vitsou E,Sykara G,Kyriopoulos J

更新日期：2012-08-01 00:00:00

abstract：BACKGROUND:Patients with grade 2 or 3 hypertension may require high-dose combination therapy to achieve blood pressure (BP) targets in a timely manner. OBJECTIVES:This study compared the effectiveness and tolerability of a single-pill combination (SPC) of telmisartan/hydrochlorothiazide 80/25 mg (T80/H25) with T80 mon...

journal_title：Clinical therapeutics

authors： Zhu DL,Bays H,Gao P,Mattheus M,Voelker B,Ruilope LM

更新日期：2012-07-01 00:00:00

abstract：BACKGROUND:Hypertension usually clusters with other cardiovascular risk factors; however, it has not been reported whether hypertension treatment has an impact on the awareness and treatment of other cardiovascular risk factors such as diabetes mellitus and hypercholesterolemia. OBJECTIVE:To analyze the effect of hype...

journal_title：Clinical therapeutics

authors： Kim KI,Kim CH

更新日期：2012-07-01 00:00:00

abstract：BACKGROUND:A sprinkle capsule formulation containing enteric-coated, delayed-release rabeprazole granules is being developed for the treatment of children with gastrointestinal reflux disease. The granules are designed to be mixed with vehicles that facilitate delivery to children, who may be unable to swallow solid fo...

journal_title：Clinical therapeutics

authors： Thyssen A,Solanki B,Treem W

更新日期：2012-07-01 00:00:00

abstract：OBJECTIVE:This study assessed the cost-effectiveness of escitalopram for the treatment of depression in the Netherlands from a societal perspective. METHODS:A decision tree model was constructed using decision analytical techniques. Data sources included published literature, clinical trials, official price/tariff lis...

journal_title：Clinical therapeutics

authors： Nuijten MJ,Brignone M,Marteau F,den Boer JA,Hoencamp E

更新日期：2012-06-01 00:00:00

abstract：BACKGROUND:Considerable clinical data on the treatment of type 2 diabetes with incretin-based therapies (glucagon-like peptide 1 receptor agonists [GLP-1RAs] and dipeptidyl-peptidase IV [DPP-4] inhibitors) are available. OBJECTIVE:This meta-analysis was performed to support the understanding of the overall evidence by...

journal_title：Clinical therapeutics

authors： Aroda VR,Henry RR,Han J,Huang W,DeYoung MB,Darsow T,Hoogwerf BJ

更新日期：2012-06-01 00:00:00

abstract：BACKGROUND:Optimal treatment regimens for infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae are not well-defined. OBJECTIVES:This study describes the treatment and outcomes in patients with urinary tract infection (UTI) caused by KPC-producing Enterobacteriaceae. METHODS:This...

journal_title：Clinical therapeutics

authors： Alexander BT,Marschall J,Tibbetts RJ,Neuner EA,Dunne WM Jr,Ritchie DJ

更新日期：2012-06-01 00:00:00

abstract：BACKGROUND:Belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulating protein, was the first biologic agent approved for, and the first drug approved in 55 years for, the treatment of systemic lupus erythematosus (SLE) by the US Food and Drug Administration (FDA). OBJECTIVE:This article reviews the curren...

journal_title：Clinical therapeutics

authors： Boyce EG,Fusco BE

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND:Sialorrhea, or drooling, is seen in the pediatric population, especially in patients with cerebral palsy and other neurodevelopmental disabilities. If medication use is warranted, anticholinergic agents are the drug of choice; however, adverse effects limit their use. Glycopyrrolate, a synthetic anticholiner...

journal_title：Clinical therapeutics

authors： Eiland LS

更新日期：2012-04-01 00:00:00

abstract：BACKGROUND:Hereditary angioedema (HAE) is a rare, potentially life-threatening autosomal dominant disease characterized by recurrent angioedema attacks that affect the skin, gastrointestinal tract, and airway, including the larynx. Pharmacologic developments in HAE treatment have culminated in the recent introduction o...

journal_title：Clinical therapeutics

authors： Riedl M

更新日期：2012-03-01 00:00:00

abstract：BACKGROUND:The prevalence of gout has been increasing. Serum uric acid (sUA) levels ≥6 mg/dL have been associated with high morbidity and increased health care utilization. OBJECTIVE:To assess the costs and patterns of health care resource utilization for patients with gout, categorized into 3 cohorts based on sUA lev...

journal_title：Clinical therapeutics

authors： Park H,Rascati KL,Prasla K,McBayne T

更新日期：2012-03-01 00:00:00

abstract：BACKGROUND:Biosimilars are defined as biologic products that are highly similar to reference products, notwithstanding minor differences in clinically inactive components, with no clinically meaningful differences between the biologic product and the reference product in terms of safety profile, purity, and potency. Du...

journal_title：Clinical therapeutics

authors： Ahmed I,Kaspar B,Sharma U

更新日期：2012-02-01 00:00:00

abstract：BACKGROUND:Although third mandibular molar extraction is a widely used and validated model of acute pain for evaluating analgesic efficacy, a large proportion of patients experience moderate or severe pain following this procedure and require analgesia. Current treatment options have been associated with safety concern...

journal_title：Clinical therapeutics

authors： Saito K,Kaneko A,Machii K,Ohta H,Ohkura M,Suzuki M

更新日期：2012-02-01 00:00:00

abstract：BACKGROUND:Aspirin is a widely used NSAID that has been extensively studied in numerous conditions. Nonprescription analgesics, such as aspirin, are frequently used for a wide variety of common ailments, including conditions such as dental pain and tension-type headache. OBJECTIVE:We sought to compare the efficacy and...

journal_title：Clinical therapeutics

authors： Gatoulis SC,Voelker M,Fisher M

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Drug treatment can defer surgical intervention in benign prostatic hyperplasia (BPH), a common disorder in elderly men, and is widely practiced. Various herbal formulations have been used for the treatment of BPH, but few have been compared with established modern medicines in head-to-head clinical trials. ...

journal_title：Clinical therapeutics

authors： Sengupta G,Hazra A,Kundu A,Ghosh A

更新日期：2011-12-01 00:00:00

abstract：BACKGROUND:Communicating potential benefits and harm to patients and payers is essential for high-quality care. However, there are no published guidelines or consensuses on how to communicate potential benefits and harm to patients and payers. OBJECTIVE:The goal of this review was to identify key elements for communic...

journal_title：Clinical therapeutics

authors： Wu R,Kemp DE,Sajatovic M,Zhao J,Calabrese JR,Gao K

更新日期：2011-12-01 00:00:00

abstract：BACKGROUND:Numerous reviews and meta-analyses of the antidepressant literature in major depressive disorders (MDD), both acute and maintenance, have been published, some claiming that antidepressants are mostly ineffective and others that they are mostly effective, in either acute or maintenance treatment. OBJECTIVE:T...

journal_title：Clinical therapeutics

authors： Vöhringer PA,Ghaemi SN

更新日期：2011-12-01 00:00:00

abstract：BACKGROUND:Patients newly diagnosed with type 2 diabetes mellitus generally initiate therapy with either metformin [Met] or a sulfonylurea [SU] drug, followed by the addition of a second agent (Met, an SU drug, or a thiazolidinedione [TZD] drug) if the diabetes is not well controlled. If necessary, the usual third line...

journal_title：Clinical therapeutics

authors： Rascati KL,Richards KM,Lopez D,Cheng LI,Wilson JP

更新日期：2011-12-01 00:00:00

abstract：BACKGROUND:Idiopathic thrombocytopenic purpura (ITP) is a relatively rare acquired autoimmune disease characterized by either decreased platelet production or increased platelet destruction leading to reduced platelet counts and increased risk of bleeding. Immune modulators have been used in treatment; however, a novel...

journal_title：Clinical therapeutics

authors： Zhang Y,Kolesar JM

更新日期：2011-11-01 00:00:00

abstract：BACKGROUND:A link between the use of alendronate and atypical diaphyseal femoral fracture has been suggested. OBJECTIVE:The goal of this study was to evaluate the benefits of alendronate in preventing rehospitalization due to hip fractures and whether its use increases risk of hospitalization for atypical diaphyseal f...

journal_title：Clinical therapeutics

authors： Hsiao FY,Huang WF,Chen YM,Wen YW,Kao YH,Chen LK,Tsai YW

更新日期：2011-11-01 00:00:00

abstract：BACKGROUND:The Intermountain Cystic Fibrosis Pediatric Center utilizes ticarcillin-clavulanate 400 mg/kg/d divided every 6 hours, (maximum 24 g/d). This dosing strategy is higher than the Food and Drug Administration (FDA)-approved package labeling. We evaluated the microbiologic efficacy of this dosing regimen. OBJEC...

journal_title：Clinical therapeutics

authors： Zobell JT,Stockmann C,Young DC,Cash J,McDowell BJ,Korgenski K,Sherwin CM,Spigarelli M,Chatfield BA,Ampofo K

更新日期：2011-11-01 00:00:00

abstract：BACKGROUND:The utilization pattern of dronedarone was unknown, especially regarding prescribers' compliance with the product's prescribing information (PI) following its availability and the implementation of the Food and Drug Administration-approved risk evaluation and mitigation strategy for the drug in the United St...

journal_title：Clinical therapeutics

authors： Gao S,Juhaeri J,Schiappacasse HA,Koren AT,Dai WS

更新日期：2011-10-01 00:00:00

abstract：BACKGROUND:Bisphosphonates are the class of medication used most widely to treat osteoporosis. Since an article reported that patients who used zoledronic acid, a bisphosphonate, had a higher proportion of atrial fibrillation (AF) in 2007, the issue of bisphosphonates and AF has become a growing concern. Due to the wid...

journal_title：Clinical therapeutics

authors： Lu PY,Hsieh CF,Tsai YW,Huang WF

更新日期：2011-09-01 00:00:00

abstract：BACKGROUND:Conflicting results using the combination of ezetimibe and statins to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS) have been reported. OBJECTIVE:The aim of this work was to assess the effectiveness of ezetimibe coadministered with statins in reducing cardiovascular...

journal_title：Clinical therapeutics

authors： Lin CF,Gau CS,Wu FL,Hsiao FY,Bai CH,Shen LJ

更新日期：2011-09-01 00:00:00

abstract：BACKGROUND:The need for an approach to measuring health results that incorporates patients' and payers' perspectives has generated a wide range of health care outcomes (HCOs), but it is yet unknown whether these HCOs are appropriate or valid for the health care decision-making process. OBJECTIVE:The goal of this study...

journal_title：Clinical therapeutics

authors： Vieta A,Badia X,Sacristán JA

更新日期：2011-09-01 00:00:00